Published in Vaccine on December 05, 2005
Reducing AD-like pathology in 3xTg-AD mouse model by DNA epitope vaccine - a novel immunotherapeutic strategy. PLoS One (2008) 1.42
DNA prime-protein boost increased the titer, avidity and persistence of anti-Abeta antibodies in wild-type mice. Gene Ther (2009) 1.13
Enhancing Th2 immune responses against amyloid protein by a DNA prime-adenovirus boost regimen for Alzheimer's disease. Immunol Lett (2007) 1.09
DNA beta-amyloid(1-42) trimer immunization for Alzheimer disease in a wild-type mouse model. JAMA (2009) 1.07
Amyloid-beta immunotherapy for Alzheimer's disease. CNS Neurol Disord Drug Targets (2010) 1.07
Transcutaneous beta-amyloid immunization reduces cerebral beta-amyloid deposits without T cell infiltration and microhemorrhage. Proc Natl Acad Sci U S A (2007) 1.04
Immunogenicity, efficacy, safety, and mechanism of action of epitope vaccine (Lu AF20513) for Alzheimer's disease: prelude to a clinical trial. J Neurosci (2013) 1.02
MER5101, a novel Aβ1-15:DT conjugate vaccine, generates a robust anti-Aβ antibody response and attenuates Aβ pathology and cognitive deficits in APPswe/PS1ΔE9 transgenic mice. J Neurosci (2013) 0.98
DNA epitope vaccine containing complement component C3d enhances anti-amyloid-beta antibody production and polarizes the immune response towards a Th2 phenotype. J Neuroimmunol (2008) 0.94
Alternative Abeta immunotherapy approaches for Alzheimer's disease. CNS Neurol Disord Drug Targets (2009) 0.92
CD4 T cells in immunity and immunotherapy of Alzheimer's disease. Immunology (2013) 0.89
Rationale for peptide and DNA based epitope vaccines for Alzheimer's disease immunotherapy. CNS Neurol Disord Drug Targets (2009) 0.89
The immunological potency and therapeutic potential of a prototype dual vaccine against influenza and Alzheimer's disease. J Transl Med (2011) 0.87
Immune modulation by adjuvants combined with diphtheria toxoid administered topically in BALB/c mice after microneedle array pretreatment. Pharm Res (2009) 0.86
Amyloid beta immunization worsens iron deposits in the choroid plexus and cerebral microbleeds. Neurobiol Aging (2013) 0.84
Early diagnostics and therapeutics for Alzheimer's disease--how early can we get there? Expert Rev Neurother (2006) 0.84
A cyclic undecamer peptide mimics a turn in folded Alzheimer amyloid β and elicits antibodies against oligomeric and fibrillar amyloid and plaques. PLoS One (2011) 0.78
Tau-Directed Immunotherapy: A Promising Strategy for Treating Alzheimer's Disease and Other Tauopathies. J Neuroimmune Pharmacol (2015) 0.78
A Perspective on Roles Played by Innate and Adaptive Immunity in the Pathobiology of Neurodegenerative Disorders. J Neuroimmune Pharmacol (2015) 0.78
Immunization with the SDPM1 peptide lowers amyloid plaque burden and improves cognitive function in the APPswePSEN1(A246E) transgenic mouse model of Alzheimer's disease. Neurobiol Dis (2010) 0.78
Immunostimulant patches containing Escherichia coli LT enhance immune responses to DNA- and recombinant protein-based Alzheimer's disease vaccines. J Neuroimmunol (2014) 0.77
Active and passive immunization strategies based on the SDPM1 peptide demonstrate pre-clinical efficacy in the APPswePSEN1dE9 mouse model for Alzheimer's disease. Neurobiol Dis (2013) 0.77
T Lymphocytes and Inflammatory Mediators in the Interplay between Brain and Blood in Alzheimer's Disease: Potential Pools of New Biomarkers. J Immunol Res (2017) 0.75
A dual vaccine against influenza & Alzheimer's disease failed to enhance anti-β-amyloid antibody responses in mice with pre-existing virus specific memory. J Neuroimmunol (2014) 0.75
Comparison of Efficacy of Preventive and Therapeutic Vaccines Targeting the N Terminus of β-Amyloid in an Animal Model of Alzheimer's Disease. Mol Ther (2017) 0.75
The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science (2002) 49.51
TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol (1989) 31.72
Alzheimer's disease: the amyloid cascade hypothesis. Science (1992) 13.80
Interferon-gamma and B cell stimulatory factor-1 reciprocally regulate Ig isotype production. Science (1987) 13.03
Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature (1999) 12.95
High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J Neurosci (2000) 9.85
Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med (2000) 8.89
Lymphokine control of in vivo immunoglobulin isotype selection. Annu Rev Immunol (1990) 7.93
Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med (2003) 7.83
A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature (2001) 7.35
A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature (2001) 6.78
Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology (2003) 6.51
Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A (2001) 5.60
Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron (2004) 5.52
Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology (2005) 5.51
Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron (2003) 4.39
Universally immunogenic T cell epitopes: promiscuous binding to human MHC class II and promiscuous recognition by T cells. Eur J Immunol (1989) 4.29
Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology (2005) 3.58
A learning deficit related to age and beta-amyloid plaques in a mouse model of Alzheimer's disease. Nature (2001) 3.28
Amyloid beta protein immunotherapy neutralizes Abeta oligomers that disrupt synaptic plasticity in vivo. Nat Med (2005) 3.28
Alzheimer's disease: a central role for amyloid. J Neuropathol Exp Neurol (1994) 3.19
Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease. Brain Pathol (2004) 3.01
Abeta vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Neurology (2005) 2.79
Epitope and isotype specificities of antibodies to beta -amyloid peptide for protection against Alzheimer's disease-like neuropathology. Proc Natl Acad Sci U S A (2003) 2.58
Evaluation of the safety and immunogenicity of synthetic Abeta42 (AN1792) in patients with AD. Neurology (2005) 2.58
Non-Fc-mediated mechanisms are involved in clearance of amyloid-beta in vivo by immunotherapy. J Neurosci (2002) 2.44
A portrait of Alzheimer secretases--new features and familiar faces. Science (2001) 2.42
Amyloid-beta immunotherapy for Alzheimer's disease: the end of the beginning. Nat Rev Neurosci (2002) 2.42
Adjuvants for human vaccines--current status, problems and future prospects. Vaccine (1995) 2.26
Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with beta-amyloid. Int Immunol (2003) 2.02
Inflammatory responses to amyloidosis in a transgenic mouse model of Alzheimer's disease. Am J Pathol (2001) 1.66
Prototype Alzheimer's disease vaccine using the immunodominant B cell epitope from beta-amyloid and promiscuous T cell epitope pan HLA DR-binding peptide. J Immunol (2005) 1.56
Abeta42 immunization in Alzheimer's disease generates Abeta N-terminal antibodies. Ann Neurol (2005) 1.51
Set back to Alzheimer vaccine studies. Nat Med (2002) 1.43
Phase 1 trial of immunological adjuvant QS-21 with a GM2 ganglioside-keyhole limpet haemocyanin conjugate vaccine in patients with malignant melanoma. Vaccine (1994) 1.28
Does my mouse have Alzheimer's disease? Genes Brain Behav (2002) 1.28
Cellular and molecular biology of Alzheimer's disease and animal models. Annu Rev Med (1994) 1.24
Safety, tolerability and immunogenicity of new formulations of the Plasmodium falciparum malaria peptide vaccine SPf66 combined with the immunological adjuvant QS-21. Vaccine (2002) 1.16
Integrating signals from IFN-gamma and IL-4 by B cells: positive and negative effects on CD40 ligand-induced proliferation, survival, and division-linked isotype switching to IgG1, IgE, and IgG2a. J Immunol (1999) 1.16
Importance of IgG2c isotype in the immune response to beta-amyloid in amyloid precursor protein/transgenic mice. Neurosci Lett (2003) 1.09
Dosing in phase II trial of Alzheimer's vaccine suspended. Lancet Neurol (2002) 1.04
Cytokine, chemokine and chemokine receptor mRNA expression in different strains of normal mice: implications for establishment of a Th1/Th2 bias. J Neuroimmunol (1999) 1.03
Immunogenic properties of multiple antigen peptide systems containing defined T and B epitopes. J Immunol (1992) 1.02
Amyloid protein and Alzheimer's disease. Sci Am (1991) 1.02
QS-21: a water-soluble triterpene glycoside adjuvant. Expert Opin Investig Drugs (1998) 1.01
Cytokine regulation of immunoglobulin isotype switching and expression. Semin Immunol (1989) 0.90
A microfluidic culture platform for CNS axonal injury, regeneration and transport. Nat Methods (2005) 7.62
Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron (2004) 5.52
Reduction of soluble Abeta and tau, but not soluble Abeta alone, ameliorates cognitive decline in transgenic mice with plaques and tangles. J Biol Chem (2006) 2.33
Gene expression changes in the course of normal brain aging are sexually dimorphic. Proc Natl Acad Sci U S A (2008) 2.29
Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with beta-amyloid. Int Immunol (2003) 2.02
Patterned cell culture inside microfluidic devices. Lab Chip (2004) 1.89
Microfluidic Multicompartment Device for Neuroscience Research. Langmuir (2003) 1.72
Prototype Alzheimer's disease vaccine using the immunodominant B cell epitope from beta-amyloid and promiscuous T cell epitope pan HLA DR-binding peptide. J Immunol (2005) 1.56
Blocking Abeta42 accumulation delays the onset and progression of tau pathology via the C terminus of heat shock protein70-interacting protein: a mechanistic link between Abeta and tau pathology. J Neurosci (2008) 1.49
Reducing AD-like pathology in 3xTg-AD mouse model by DNA epitope vaccine - a novel immunotherapeutic strategy. PLoS One (2008) 1.42
Exercise alters the immune profile in Tg2576 Alzheimer mice toward a response coincident with improved cognitive performance and decreased amyloid. J Neuroinflammation (2008) 1.38
Blocking IL-1 signaling rescues cognition, attenuates tau pathology, and restores neuronal β-catenin pathway function in an Alzheimer's disease model. J Immunol (2011) 1.36
Alzheimer's disease peptide epitope vaccine reduces insoluble but not soluble/oligomeric Abeta species in amyloid precursor protein transgenic mice. J Neurosci (2007) 1.31
Anti-A beta 1-11 antibody binds to different beta-amyloid species, inhibits fibril formation, and disaggregates preformed fibrils but not the most toxic oligomers. J Biol Chem (2007) 1.30
Phagocytosis of amyloid-beta and inflammation: two faces of innate immunity in Alzheimer's disease. J Alzheimers Dis (2007) 1.28
A transgenic Alzheimer rat with plaques, tau pathology, behavioral impairment, oligomeric aβ, and frank neuronal loss. J Neurosci (2013) 1.17
Generation and characterization of the humoral immune response to DNA immunization with a chimeric beta-amyloid-interleukin-4 minigene. Eur J Immunol (2003) 1.12
Synaptic genes are extensively downregulated across multiple brain regions in normal human aging and Alzheimer's disease. Neurobiol Aging (2012) 1.10
Importance of IgG2c isotype in the immune response to beta-amyloid in amyloid precursor protein/transgenic mice. Neurosci Lett (2003) 1.09
Frontal cortex neuropathology in dementia pugilistica. J Neurotrauma (2012) 1.08
ABCC9 gene polymorphism is associated with hippocampal sclerosis of aging pathology. Acta Neuropathol (2014) 1.07
Antitumor efficacy of DNA vaccination to the epigenetically acting tumor promoting transcription factor BORIS and CD80 molecular adjuvant. J Cell Biochem (2006) 1.07
Ovol2 suppresses cell cycling and terminal differentiation of keratinocytes by directly repressing c-Myc and Notch1. J Biol Chem (2009) 1.05
Selective apoptosis of breast cancer cells by siRNA targeting of BORIS. Biochem Biophys Res Commun (2008) 1.03
Fas and Fas ligand are associated with neuritic degeneration in the AD brain and participate in beta-amyloid-induced neuronal death. Neurobiol Dis (2003) 1.03
Novel Abeta peptide immunogens modulate plaque pathology and inflammation in a murine model of Alzheimer's disease. J Neuroinflammation (2005) 1.03
Immunogenicity, efficacy, safety, and mechanism of action of epitope vaccine (Lu AF20513) for Alzheimer's disease: prelude to a clinical trial. J Neurosci (2013) 1.02
Brain-derived neurotrophic factor-dependent synaptic plasticity is suppressed by interleukin-1β via p38 mitogen-activated protein kinase. J Neurosci (2012) 1.01
Experimental investigation of antibody-mediated clearance mechanisms of amyloid-beta in CNS of Tg-SwDI transgenic mice. J Neurosci (2007) 1.00
Reductions in amyloid-beta-derived neuroinflammation, with minocycline, restore cognition but do not significantly affect tau hyperphosphorylation. J Alzheimers Dis (2010) 1.00
Aging and cerebrovascular dysfunction: contribution of hypertension, cerebral amyloid angiopathy, and immunotherapy. Ann N Y Acad Sci (2010) 0.99
A fibril-specific, conformation-dependent antibody recognizes a subset of Abeta plaques in Alzheimer disease, Down syndrome and Tg2576 transgenic mouse brain. Acta Neuropathol (2009) 0.98
Mixed cerebrovascular disease and the future of stroke prevention. Transl Stroke Res (2012) 0.97
Mannan-Abeta28 conjugate prevents Abeta-plaque deposition, but increases microhemorrhages in the brains of vaccinated Tg2576 (APPsw) mice. J Neuroinflammation (2008) 0.97
Novel approaches for immunotherapeutic intervention in Alzheimer's disease. Neurochem Int (2006) 0.96
Refinement of a DNA based Alzheimer's disease epitope vaccine in rabbits. Hum Vaccin Immunother (2013) 0.94
Bapineuzumab alters aβ composition: implications for the amyloid cascade hypothesis and anti-amyloid immunotherapy. PLoS One (2013) 0.94
DNA epitope vaccine containing complement component C3d enhances anti-amyloid-beta antibody production and polarizes the immune response towards a Th2 phenotype. J Neuroimmunol (2008) 0.94
Aspirin-triggered lipoxin A4 stimulates alternative activation of microglia and reduces Alzheimer disease-like pathology in mice. Am J Pathol (2013) 0.93
Loss of muscarinic M1 receptor exacerbates Alzheimer's disease-like pathology and cognitive decline. Am J Pathol (2011) 0.93
Elicitation of T cell responses to histologically unrelated tumors by immunization with the novel cancer-testis antigen, brother of the regulator of imprinted sites. J Immunol (2007) 0.93
External force-assisted cell positioning inside microfluidic devices. Biomed Microdevices (2007) 0.92
The induction of the TNFalpha death domain signaling pathway in Alzheimer's disease brain. Neurochem Res (2003) 0.92
Cancer-testis antigen, BORIS based vaccine delivered by dendritic cells is extremely effective against a very aggressive and highly metastatic mouse mammary carcinoma. Cell Immunol (2011) 0.91
Therapeutic modulation of cerebral microhemorrhage in a mouse model of cerebral amyloid angiopathy. Stroke (2011) 0.91
Elevated stearoyl-CoA desaturase in brains of patients with Alzheimer's disease. PLoS One (2011) 0.90
Expression of the epigenetic factor BORIS (CTCFL) in the human genome. J Transl Med (2011) 0.90
Delivery of a DNA vaccine for Alzheimer's disease by electroporation versus gene gun generates potent and similar immune responses. Neurodegener Dis (2012) 0.90
Amyloid-β peptide binds to cytochrome C oxidase subunit 1. PLoS One (2012) 0.89
Connective tissue fibroblast properties are position-dependent during mouse digit tip regeneration. PLoS One (2013) 0.89
Immunization with amyloid-beta attenuates inclusion body myositis-like myopathology and motor impairment in a transgenic mouse model. J Neurosci (2009) 0.89
Down syndrome and dementia: seizures and cognitive decline. J Alzheimers Dis (2012) 0.89
An amyloid β42-dependent deficit in anandamide mobilization is associated with cognitive dysfunction in Alzheimer's disease. Neurobiol Aging (2011) 0.88
The immunological potency and therapeutic potential of a prototype dual vaccine against influenza and Alzheimer's disease. J Transl Med (2011) 0.87
The bradykinin B1 receptor regulates Aβ deposition and neuroinflammation in Tg-SwDI mice. Am J Pathol (2013) 0.86
Active and passive Abeta-immunotherapy: preclinical and clinical studies and future directions: part I. CNS Neurol Disord Drug Targets (2009) 0.86
CD80 (B7-1) and CD86 (B7-2) are functionally equivalent in the initiation and maintenance of CD4+ T-cell proliferation after activation with suboptimal doses of PHA. DNA Cell Biol (2002) 0.84